Objective-Gain-of-function mutations of PCSK9 (proprotein convertase subtilisin/kexin type 9) lead to hypercholesterolemia.
A ngiotensin II (AngII) infusion in mice induces abdominal aortic aneurysms (AAAs) and has been used in many studies on mechanisms of the disease. [1] [2] [3] [4] Although AngII induces AAAs in both normocholesterolemic and hypercholesterolemic mice, 1,5-7 incidence of AAAs in normocholesterolemic mice is only 10% to 20%, which is an impediment to exploring molecular mechanisms of AAAs. Currently, to determine molecular mechanisms of AngII-induced AAAs, most studies bred genetically manipulated mice to either apolipoprotein E −/− or low-density lipoprotein (LDL) receptor −/− mice. This method is time-and cost-consuming because it takes >2 years to develop a colony containing sufficient numbers of compound-deficient mice. 8, 9 There are also concerns on genetic equivalence between groups, and it is possible that development of compound deficiency is difficult because of genetic loci and other issues. 8, 9 PCSK9 (proprotein convertase subtilisin/kexin type 9) plays an important role in lipoprotein metabolism through regulating LDL receptor homeostasis. 10 Gain-of-function mutations of human PCSK9 protein are associated with autosomal dominant hypercholesterolemia. 11 Two groups have studied effects of a well-characterized gain-of-function mutation in humans, D374Y, on atherosclerosis in mice using adenoassociated virus (AAV)-mediated gene transfer approach. 12, 13 This approach, by a single injection of AAV containing human PCSK9D374Y mutation or its mouse equivalent, D377Y mutation, leads to rapid increase of plasma cholesterol concentrations in C57BL/6 mice. As a consequence, this single injection accelerates atherosclerosis in mice. In this study, we have demonstrated that AAV-delivered mouse PCSK9D377Y mutation provides a rapid augmentation of AngII-induced AAAs in male C57BL/6 mice.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Dose-Response Curve of AAV Infection With PCSK9D377Y Gain-of-Function Mutation in C57BL/6 Mice
To evaluate expression efficiency and stability of AAV vectors, we measured plasma PCSK9 concentrations on week 0 (before AAV injection) and 2 and 6 weeks after AAV injection. At baseline (week 0), plasma PCSK9 concentrations were 112±7 ng/mL (mean±SEM of 28 mice). The low plasma PCSK9 concentrations remained unchanged in C57BL/6 mice receiving AAV vector containing a null insert ( Figure 1A ). Plasma PCSK9 concentrations were profoundly increased 2 weeks post injection and remained high during 6 weeks of Western diet feeding in C57BL/6 mice infected with an AAV vector expressing PCSK9D377Y mutation. There was no difference in plasma PCSK9 concentrations between mice infected with 10×10 10 and 30×10 10 genomic copies ( Figure 1A) . Consistent with increased plasma PCSK9 concentrations, plasma cholesterol concentrations were markedly and continuously increased during the 6 weeks of Western diet feeding ( Figure 1B ). All 3 doses of PCSK9D377Y.AAV increased atherosclerotic lesions ( Figure 1C ), whereas only intermediate and high doses of PCSK9D377Y mutation led to augmentation of AngII-induced AAAs ( Figure 1D ). Because the intermediate and high doses had no differences on increasing plasma cholesterol concentrations and AngII-induced AAAs, the following studies only used the intermediate dose.
Although PCSK9D377Y.AAV infection led to increased plasma PCSK9 concentrations in mice fed either normal or Western diet, increases of plasma PCSK9 were more pronounced in mice fed Western diet and were positively correlated with increases of plasma cholesterol concentrations ( Figure I 
C57BL/6 Mice Were the Most Susceptible to AAV Infection of Mouse PCSK9D377Y Mutation
In addition to C57BL/6 mice, many other normocholesterolemic mouse strains have been used as background strains for genetic manipulations. Therefore, we compared infection of AAV expressing mouse PCSK9D377Y in 5 commonly used normocholesterolemic mouse strains ( Figure II in the online-only Data Supplement). Although plasma PCSK9 concentrations at baseline were comparable, these 5 strains had different response to this AAV infection. C57BL/6 mice were the most susceptible to this AAV infection, whereas plasma PCSK9 concentrations were increased minimally in BALB/c mice. Consistent with plasma PCSK9 and cholesterol concentration changes, only C57BL/6 mice had significant increases of AngII-induced AAAs.
Infection of PCSK9D377Y.AAV in C57BL/6 Mice Had Comparable Effects as LDL Receptor −/− Mice on AngII-Induced AAAs
At baseline, LDL receptor −/− mice had >10-fold higher plasma PCSK9 concentrations compared with C57BL/6 mice ( Figure 2A ). During Western diet feeding and AngII infusion, plasma PCSK9 concentrations were not significantly changed in LDL receptor −/− mice, which were lower than C57BL/6 mice infected with PCSK9D377Y.AAV (Figure 2A ). C57BL/6 mice infected with PCSK9D377Y.AAV had rapid increases of plasma cholesterol concentrations, but were lower than LDL receptor −/− mice fed same Western diet during the study ( Figure 2B ). Both groups had higher non-high-density lipoprotein cholesterol as demonstrated by size exclusive chromatography ( Figure 2C ). There were no differences of atherosclerotic lesion size and aortic dilation of the suprarenal region between C57BL/6 mice infected with PCSK9D377Y. AAV and LDL receptor −/− mice ( Figure 2D and 2E).
Reduced Plasma PCSK9 Concentrations Did Not Reduce AngII-Induced AAAs in LDL Receptor −/− Mice
To determine whether hypercholesterolemia augmented AngII-induced AAAs independent of enhanced PCSK9 activity, a mouse PCSK9 antisense oligonucleotide was injected into male LDL receptor −/− mice fed Western diet and infused with AngII. Although inhibition of PCSK9 led to an 86% reduction of plasma PCSK9 concentrations, it did not reduce AngII-induced AAAs ( Figure III in the online-only Data Supplement).
Discussion
Two recent studies have demonstrated that infection of AAV expressing either the human PCSK9D374Y mutation or the equivalent mouse PCSK9D377Y mutation leads to rapid increases of plasma cholesterol concentrations, which consequently accelerates atherosclerosis in C57BL/6 mice. 12, 13 Our study demonstrates that PCSK9 gain-of-function mutationinduced increases of plasma cholesterol concentrations augment AngII-induced AAAs in C57BL/6 mice.
We used AAVs expressing mouse PCSK9D377Y gain-offunction mutation. Dose responses were defined based on the report by Bjorklund et al. 12 AAVs were administered through intravenous route in the 2 published studies. 12, 13 In contrast, our study used intraperitoneal injection, which was much easier to apply. This route provided comparable effects on increasing plasma cholesterol concentrations as the reported intravenous injection. 12 This injection route was also used in our previous studies for AAV vector expressing mouse angiotensinogen, which led to profound increases of plasma angiotensinogen concentrations in mice lacking systemic angiotensinogen. 14, 15 Collectively, our study provides evidence that intraperitoneal injection is a feasible method for efficient AAV infection to deliver mouse PCSK9D377Y mutation. Consistent with the 2 published studies, 12,13 mouse PCSK9D377Y.AAV-infected C57BL/6 mice fed a normal diet had much lower plasma PCSK9 concentrations, whereas Western diet feeding strikingly increased plasma PCSK9 and cholesterol concentrations. It is also worth noting that plasma PCSK9 concentrations are 4-to 5-fold higher in C57BL/6 mice injected with human PCSK9D374Y.AAV 12 than in C57BL/6 mice injected with mouse PCSK9D377Y.AAV as found in our study although increases of plasma cholesterol concentrations are similar between these 2 studies when fed similar fat-enriched diet.
Nonstandard Abbreviations and Acronyms
Roche-Molina et al 13 report that C57BL/6 mice are more susceptible to human PCSK9D374Y.AAV-induced increases of plasma cholesterol concentrations and thereby the development of atherosclerosis, compared with 129 and FVB (friend leukemia virus B strain) mouse strains. In extending this, we found that among 5 normocholesterolemic mouse strains, C57BL/6 mice were the most susceptible to mouse PCSK9D377Y.AAV infection-induced increases of plasma PCSK9 and cholesterol concentrations, thereby the development of atherosclerosis and AAAs. Therefore, C57BL/6 mice are an optimal strain infecting with PCSK9D377Y.AAV to study AngII-induced AAAs.
PCSK9 regulates plasma cholesterol concentrations through intracellular degradation of LDL receptors. 10, 11, 16, 17 In agreement with the 2 recent studies, 12, 13 lipoprotein cholesterol distribution in C57BL/6 mice infected with mouse PCSK9D377Y.AAV and fed a Western diet is equivalent to that in LDL receptor −/− mice fed the same diet. Although plasma cholesterol concentrations were significantly lower in C57BL/6 mice expressing PCSK9D377Y, these 2 mouse strains had comparable development of atherosclerosis and AngII-induced AAAs. Inhibition of PCSK9 by mouse PCSK9 antisense oligonucleotides in LDL receptor −/− mice did not reduce AngIIinduced AAAs, providing evidence that hypercholesterolemia, rather than increases of PCSK9 activity, contributes to augmented AAA formation in AngII-infused mice. This finding is consistent with our previous study using multiple mouse models. 1 This finding is also consistent with what has been reported in 2 prospective studies that incidence of AAA is associated with plasma total cholesterol concentrations in humans. 18, 19 Although our studies did not observe difference of atherosclerotic lesion size between C57BL/6 mice infected with mouse PCSK9D377Y.AAV and LDL receptor −/− mice, it is unclear whether their different plasma cholesterol concentrations would cause different effects on atherosclerosis in a long-term manner. In addition to degradation of LDL receptor, PCSK9 is also known to have LDL receptor-independent effects. [20] [21] [22] Therefore, it will also be important to determine whether PCSK9D377Y mutation has effects on atherosclerosis and AAAs beyond regulating degradation of LDL receptors.
Overall, AAV infection of C57BL/6 mice with a gain-offunction mutation of mouse PCSK9 that is steadily expressed provides a rapid mode of augmenting AngII-induced AAAs. • A single intraperitoneal injection of AAV containing mouse PCSK9D377Y increases plasma cholesterol concentrations in C57BL/6 mice.
• AAV infection with mouse PCSK9D377Y augments AngII-induced AAAs in male C57BL/6 mice, but not in other normalipidemic mouse strains.
• AAV infection with mouse PCSK9D377Y in C57BL/6 mice has equivalent effects as LDL receptor −/− mice on augmentation of AngII-induced AAAs.
